title: [Pain therapy with rhenium-186 HEDP in multiple bone metastases].
abstract: OBJECTIVE
  Therapeutic means for patients with painful bony metastases are strongly limited. In these patients, a systemic therapy with isotopes can be helpful. The aim of this study was to evaluate the efficacy of rhenium-186 HEDP for pain palliation in patients with disseminated bone metastases.
  
  
  METHODS
  30 patients taking analgesics because of bone pain received one or more injection of 1295 MBq 186Re HEDP for pain palliation.
  
  
  RESULTS
  In 70% of the patients, therapy resulted in a significant reduction of pain. The average duration of pain relief was 4 weeks (1 week-2.5 months). The main side effects of therapy were a decrease of platelets (aver. 30000/microliters) and an increase of pain for 1-2 days (flare-phenomenon).
  
  
  CONCLUSIONS
  Therapy with rhenium-186 HEDP can be used complementarily to analgesic therapy in patients with painful, disseminated bone metastases.
authors.affiliation: Aus der Klinik für Nuklearmedizin, Universität Bonn, Deutschland.
authors.forename: H
authors.initials: H
authors.lastname: Palmedo
authors.forename: H
authors.initials: H
authors.lastname: Bender
authors.forename: A
authors.initials: A
authors.lastname: Schomburg
authors.forename: F
authors.initials: F
authors.lastname: Grünwald
authors.forename: G
authors.initials: G
authors.lastname: Schöneich
authors.forename: P
authors.initials: P
authors.lastname: Zamorra
authors.forename: K
authors.initials: K
authors.lastname: Reichmann
authors.forename: C
authors.initials: C
authors.lastname: Dierke-Dzierzon
authors.forename: P
authors.initials: P
authors.lastname: Mallmann
authors.forename: H J
authors.initials: HJ
authors.lastname: Biersack
mesh_terms: D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000532:radiotherapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000503:physiopathology / Q000532:radiotherapy; D004164:Diphosphonates; D012968:Etidronic Acid / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; D010146:Pain; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000503:physiopathology / Q000532:radiotherapy; D011868:Radioisotopes / Q000627:therapeutic use*; D012211:Rhenium / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013997:Time Factors; D014055:Tomography, Emission-Computed
chemical_list: D004164:Diphosphonates; D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; D011868:Radioisotopes; C033905:technetium Tc 99m 1,1-diphosphonopropane-2,3-dicarboxylic acid; C101598:rhenium-186 HEDP; D012211:Rhenium; D012968:Etidronic Acid
vernacular_title: Schmerztherapie mit Rhenium-186 HEDP bei multiplen Knochenmetastasen.